newsU.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)First treatment to demonstrate superior benefit in a Phase 3…27 January 2012 | By PfizerFirst treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
newsPfizer presents new Phase 3 dataPfizer Inc. announced data from the pivotal Phase 3 AXIS…18 May 2011 | By PfizerPfizer Inc. announced data from the pivotal Phase 3 AXIS 1032 trial. Patients with previously treated advanced RCC, axitinib extended progression-free survival...